Close Menu

Mass Spec

News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.

The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.

The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.

The study combined large-scale protein post-translational modification datasets with protein-protein interaction data to profile cell signaling in lung cancer.

At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.

The recent study highlights strengths and weaknesses of numerous platforms and may help end users choose the best assay for their circumstances.